User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Global Market Analysis.....II-1
Sanofi-Aventis – The Only Drug Maker for ALS.....II-1
Rilutek.....II-1
1$100
   Prevalence and Incidence of ALS.....II-2
The United States.....II-2
Canada.....II-2
1$100
   Table 1: Mortality Rate of ALS in Canada - A Historic Review (includes corresponding Graph/Chart).....II-3
The United Kingdom.....II-3
New Zealand.....II-3
Australia.....II-3
Table 2: Mortality Rate in Australia for Years 2005 through 2007(includes corresponding Graph/Chart).....II-3
1$350
   Major Types of ALS.....II-41$100
   Etiology.....II-51$100
   Exact Causes of ALS Still Unknown.....II-6
Major Milestones in ALS Treatment Arena.....II-6
Diagnosis.....II-6
1$100
   Symptoms of ALS.....II-7
Initial symptoms.....II-7
1$100
   Emerging Symptoms.....II-8
Use of BiPAP, IPPV and Mechanical Respirators in ALS.....II-8
Measures to Deal with ALS Problems.....II-8
1$100
   Treatment.....II-9
Symptomatic Treatment.....II-9
2$125
   Neurotrophic Factors.....II-11
Insulin-like Growth Factor.....II-11
Vascular endothelial growth factor.....II-11
Sangamo BioSciences to Develop SB 509.....II-11
1$100
   Smaller Molecules.....II-12
RNA Interference.....II-12
Stem Cells Offer New Hope.....II-12
Studies on Stem Cells.....II-12
1$100
   LTC to Develop New Lou Gehrig's Disease Models.....II-13
Herbal Treatment.....II-13
Lithium: A potential Treatment for ALS.....II-13
Advancements in ALS Genetics.....II-13
1$100
   Select Pipeline Drugs for ALS Under Clinical Trials (2009).....II-141$100
   CytRx Initiates Phase 2/3 Clinical Trial for Arimoclomol.....II-15
New Treatment for ALS Patients.....II-15
KNS-760704 Receives Orphan Designation.....II-15
KNS-760704 Enters Phase 2 Study.....II-15
1$100
   Maas Biolab SBIR Initiates Phase 2 for Cyclosporin.....II-16
Researchers Identify New Gene for ALS.....II-16
1$100
   Merck to Purchase Insmed’s Assets.....II-17
NeuroNova Signs Agreement with Genentech.....II-17
Insmed Inks a Deal with IDIS to Organize NPPs for IPLEX™.....II-17
1$100
   Teva to Extend Branded Products in Niche Specialty Diseases.....II-18
Asklepios and ALS TDI Develop Latest Therapeutic Delivery Alternatives for ALS
  Treatment.....II-18
Medicare Extends DME Coverage of HFCWO to Cure Neuromuscular Disorders.....II-18
Neuralstem and Hospital of Taiwan Collaborate for Development of Neural Stem Cell
  Therapies.....II-18
1$100
   Life Technologies to Create Neurodegenerative Disease Models.....II-19
Medicare Extends the Coverage of HFCWO to Cure Neuromuscular Disorders.....II-19
Sygnis Obtains Orphan Drug Status for AX200 in Spinal Cord Injury Treatment.....II-19
Insmed Obtains Royalty-Free Global Rights for IPLEXTM.....II-19
1$100
   Q Therapeutics Collaborates with Johns Hopkins Research Team.....II-20
Aldagen to Collaborate with UC Davis.....II-20
ALS TDI Collaborates with CSC.....II-20
ALS TDI and Allen Institute for Brain Science Enter into Agreement.....II-20
1$100
   Amorfix Completes Research Partnership with Biogen Idec.....II-21
Isis Receives Orphan Drug Designation.....II-21
Prize4Life Endorses BrainStorm to Develop ALS Cure.....II-21
1$100
   ALS TDI Selects Microbix to Manufacture Adenoviruses.....II-22
Maas BiolAB Receives SBIR Grant.....II-22
Neuralstem Collaborates with University of Michigan.....II-22
ALS TDI and MDA Collaborate.....II-22
1$100
   Aeolus Pharmaceuticals, Inc. (US).....II-23
Amorfix Life Sciences Ltd. (Canada).....II-23
Avicena Group, Inc. (US).....II-23
Ceregene, Inc. (US).....II-23
1$100
   CytRx Corporation (US).....II-24
Genzyme Corporation (US).....II-24
Isis Pharmaceuticals, Inc. (US).....II-24
1$100
   Knopp Neurosciences (US).....II-25
Maas Biolab (US).....II-25
NeuroNova AB (Sweden).....II-25
1$100
   Sygnis Pharma AG (Germany).....II-26
Teva Pharmaceutical Industries Ltd. (Israel).....II-26
Trophos SA (France).....II-26
1$100
   Northeast Amyotrophic Lateral Sclerosis Consortium (US).....II-27
Muscular Dystrophy Association (MDA).....II-27
The ALS Association.....II-27
ALS Society of Canada.....II-27
ALS Therapy Development Institute.....II-27
1$100
   Motor Neurone Disease Research Institute of Australia.....II-281$100
   Table 3: World Recent Past, Current & Future Analysis for Lou Gehrig's Disease by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-291$350
   Table 4: World 10-Year Perspective for Lou Gehrig's Disease by Geographic Region – Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-301$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com